Ferric carboxymaltose meets primary goal of anemia treatment study

07/12/2013 | PharmaTimes (U.K.)

Ferinject, or intravenous ferric carboxymaltose, met the main goal of a clinical trial by significantly reducing the use of erythropoiesis-stimulating agents and transfusions among patients with non-dialysis-dependent chronic kidney disease. More than 600 patients participated in the international, 56-week study. They received either oral iron or 1,000 milligrams of ferric carboxymaltose initially and more as needed.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA